On February 17, 2020, Marizyme, Inc. entered into an employment agreement (the “Agreement”) with Ralph Makar pursuant to which Mr. Makar agreed to become the Company's President and Chief Executive Officer effective on or about April 1, 2020, subject to the Company's obtaining director and officer liability insurance.
Effective upon Mr. Makar's taking office as the Company's Chief Executive Officer, Nicholas P. DeVito will step down as Interim Chief Executive Officer. Mr. DeVito will remain as the Company's Interim Chief Financial Officer.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
MARIZYME, INC. 
